Drugs / Sanofi H5N1 Antigen
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT01317758 | May 2011 → Sep 2012 | influenza | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Sanofi H5N1 Antigen | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01317758 ↗ |
| Modality | Vaccine | “Subvirion inactivated monovalent influenza A/H5N1 (Hemagglutinin (HA) of A/Indonesia/05/2005) virus vaccine manufactured by sanofi pasteur” NCT01317758 ↗ |
| Route | Intramuscular | “intramuscular subvirion inactivated monovalent influenza A/H5N1 virus vaccine” NCT01317758 ↗ |